skip to main content

Prostate Cancer

Rogel researchers receive $4M through Prostate Cancer Foundation’s inaugural TACTICAL awards program

Principal investigator Arul Chinnaiyan, M.D., Ph.D., will lead a $4 million project that will employ a suite of cutting-edge drug development techniques to develop an effective inhibitor of MYC, a major driver of about 70% of all cancers, including prostate cancer.

Lower prostate cancer screening rates associated with subsequent increase in advanced cancers

In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.

Some prostate treatments may rewire the tumors, research suggests

Drugs like enzalutamide that inhibit male hormones from activating the androgen receptor have been used to treat advanced prostate cancer for more than a decade. While successful in most cases, these drugs can eventually stop working, but there is a limited understanding about how this change occurs.

Living with Stage 4 Prostate Cancer

After being diagnosed with prostate cancer, Scott Ward learned it had spread and was stage 4, advanced cancer. He shares how this devastating news impacted how he views life and how he's worked to create a legacy for his son.

Men taking common prostate cancer medication plus hormone therapy may be at risk of side effects

Men with advanced prostate cancer taking abiraterone or enzalutamide plus hormone therapy were at higher risk of serious medical issues than their peers undergoing hormone therapy alone.

How prostate cancer research led to a prestigious award

In 2005, Arul Chinnaiyan, M.D., Ph.D., and his lab found when a gene regulated by androgens called TMPRSS2 fuses with a transcription factor called ERG, it triggers the development of prostate cancer. This gene fusion was the first ever identified in solid tumors. In the nearly two decades since, the Chinnaiyan lab has refined its discovery, understanding how the hormone androgen regulates this gene fusion and developing a urine-based screening test to better detect prostate cancer.

Arul Chinnaiyan awarded prestigious Sjoberg Prize for cancer research

Arul M. Chinnaiyan, M.D., Ph.D., was awarded the 2022 Sjöberg Prize by the Royal Swedish Academy of Sciences, which also awards Nobel Prizes. Chinnaiyan is being honored for the discovery of recurrent gene fusions in prostate cancer, a groundbreaking finding initially published in 2005 that has led to a better understanding of how prostate cancer develops and improved methods to detect the disease.

Researchers discover way to use the power of immunotherapy for advanced prostate cancer

Researchers led by the University of Michigan Rogel Cancer Center started with a simple thread: an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells. This is the most challenging type of prostate cancer – advanced disease that has become resistant to hormone-based treatment.

New UPSeq Test Holds Promise for Detecting Aggressive Prostate Cancer

The Urine Prostate Seq test, or UPSeq for short, uses next-generation genomic sequencing to analyze urine collected from men following a digital rectal exam.

A New Urine Test is Very Accurate at Detecting Aggressive Prostate Cancer

The MyProstateScore test measures levels of cancer-specific genes in a patient’s urine. It's based on U-M research that half of all prostate tumors harbor a certain genetic anomaly in which the genes TMPRSS2 and ERG relocate on a chromosome and fuse together -- creating an on-switch for prostate cancer development.